Injection training for the 2026 at-home Leqembi regimen means supervised doses in clinic before a patient or caregiver injects at home. Access runs through specialty pharmacy, and Medicare Part B can cover treatment when prescribed per label by a registry-participating physician.
Leqembi Iqlik (lecanemab-irmb) is an anti-amyloid drug for early Alzheimer's disease. According to Eisai's July 13, 2026 approval notice, the initiation dose is 500 mg once weekly as two 250-mg autoinjector injections. It is only for mild cognitive impairment or mild dementia with confirmed amyloid.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can use the at-home regimen?
- What does injection training involve?
- How do you get the autoinjectors?
- What will Medicare pay?
- What clinic monitoring continues after training?
Who can use the at-home regimen?
A MedicareFAQ summary of CMS rules states treatment is only for mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid-beta pathology. Confirmation requires PET or cerebrospinal fluid testing. A memory-clinic workup usually comes before any prescription.
Eisai reports FDA also cleared a 360-mg weekly maintenance injection after 18 months of IV or subcutaneous treatment. That preserves a start-IV-then-switch path for some patients. The choice depends on diagnosis, amyloid result, and physician judgment.
- Early Alzheimer's diagnosis at the mild impairment or mild dementia stage
- Positive amyloid PET or spinal-fluid test
- Prescription consistent with the FDA label
- Physician participating in the required registry for Medicare coverage
What does injection training involve?
Initiation must occur under healthcare-provider supervision, with direct guidance for at least two consecutive doses before home use, according to the FDA label republished by Drugs.com Pro. Training is hands-on, not video-only. The patient and any home helper learn together.
Bring the person who will give shots at home to both supervised visits. Ask what normal injection-site effects look like, how to store and check autoinjectors, and whom to call with problems. Leave with a written home plan and follow-up dates.
- Attend supervised doses in clinic
- Practice preparation, injection, and disposal with direct guidance
- Show the trainer that home injection can be done safely
- Confirm MRI, check-in, and refill schedules before leaving
How do you get the autoinjectors?
Eisai said initiation-dose autoinjectors moved through specialty pharmacy starting in late August 2026. The named network was CareMed and Walgreens Specialty pharmacies. Expect shipment to home or clinic, not a retail pickup.
Eisai also offers the LEQEMBI Companion program for coverage and copay-assistance navigation. Its Patient Assistance Program supplies free drug to eligible uninsured patients meeting financial-need criteria. Ask the prescribing clinic to refer early so pharmacy enrollment does not delay training.
What will Medicare pay?
Medicare Part B covers Leqembi under the anti-amyloid national coverage determination when used per label by a registry-participating physician, according to the MedicareFAQ summary of CMS rules. Coverage is conditional, not automatic. Label use and registry participation both matter.
That summary puts 2026 cost-sharing at about 80% paid by Medicare after the $283 Part B deductible. A Medigap or other secondary plan may handle much of the remainder. Ask Companion staff and the clinic biller to estimate deductibles, coinsurance, and refill billing before training starts.
What clinic monitoring continues after training?
Leqembi carries FDA's boxed warning for amyloid-related imaging abnormalities, with edema and microhemorrhage, according to the Drugs.com overview. The overview calls for a baseline brain MRI and scheduled follow-up MRIs. Vigilance is especially important during the first 14 weeks.
Home injections do not replace brain-safety visits. Keep every MRI appointment even when shots feel routine. Report headache, confusion, dizziness, vision change, or unusual weakness promptly and keep all MRI appointments even if injections feel routine.
